Jayson Punwani

Managing Director at Abingworth

Jayson joined Abingworth’s Menlo Park office in November 2021, bringing with him more than 20 years of experience in venture investing, start-up leadership, technology transfer, and academic research within the life sciences industry.

Previously, Jayson was a Senior Partner at Takeda Ventures, the corporate venture capital arm of Takeda Pharmaceuticals, where he focused on early-stage biotech investments. He led investments in and was on the board of, VelosBio (acquired by Merck), Xilio (NASDAQ: XLO), StrideBio, and Coho Therapeutics. He also served as a member of the board of directors for Armagen (acquired by JCR) and Palleon Pharmaceuticals. Prior to Takeda, Jayson was a Senior Principal at Pappas Ventures where he played a key role in investments in CoLucid (acquired by Eli Lilly), Aura Biosciences (NASDAQ: AURA), Lumena Pharmaceutics (acquired by the Shire), and Glycomine (also an Abingworth portfolio company). He started his career as a research scientist in the cardiovascular drug discovery group at Bristol Myers Squibb.

Location

Menlo Park, United States

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices